524
Views
17
CrossRef citations to date
0
Altmetric
Research Article

Validation of the THI-12 questionnaire for international use in assessing tinnitus: A multi-centre, prospective, observational study

, , &
Pages 671-677 | Received 31 Oct 2011, Accepted 21 Dec 2011, Published online: 20 Feb 2012
 

Abstract

Objective: To investigate and confirm the reliability and validity of the tinnitus handicap inventory12 (THI-12) in various countries and languages. Design: Prospective, observational study conducted in seven countries, using linguistically harmonized versions of the THI-12 in six languages. These were evaluated for test-retest reliability, internal consistency reliability, known-groups validity, and construct validity. Basic psychometric properties of supporting instruments were compared. Questionnaires were completed by the subjects at baseline and again after 12–30 days. Study sample: Adults with a clinical diagnosis of subjective tinnitus. Results: An exploratory factor analysis of the THI-12 items for the U.S. study population at baseline revealed a single common factor of high eigenvalue. Confirmatory factor analysis supported this in the separate countries. Test-retest reliability was moderate to high, and the conclusions were supported by a known-groups analysis; correlations with other scales expected to support construct validity were moderate. Conclusions: The THI-12 total score showed acceptable psychometric properties for all countries tested. The relationships between the THI-12 and the one-month and one-week versions of the TRS and TSS were similar and convergent. The THI-12 is thus a promising diagnostic tool for assessing treatment effects in multi-cultural and multi-lingual trials on tinnitus therapy.

Acknowledgements

Data were presented in part at 4th International Tinnitus Research Initiative (TRI) Meeting: Frontiers in Tinnitus Research, June 8–11, 2010, in Dallas, USA. This study was supported by Merz Pharmaceuticals.

Declaration of interest: Ulli S. Bankstahl, Roman Görtelmeyer, and Alexander Gebauer are employees of Merz Pharmaceuticals. Eric P. Elkin is an employee of ICON Late Phase & Outcomes Research, a division of ICON plc.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.